As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board
Expect some pipeline adjustments at Enanta Pharmaceuticals in the coming years, because new CMO Scott Rottinghaus thinks the antiviral biotech can expand its horizons while also figuring out a way to address the yearslong Covid pandemic with an expected Phase II launch later this year.
“I would like to take a look at what we have as possibilities coming out of the lab. We have such a strong discovery program,” Rottinghaus told Endpoints News. “I don’t think we need to be limited to antivirals here at Enanta; we can take a broader look at some other therapeutic areas.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.